About US
Contact us
-
Johnson & Johnson accuses former employee of taking thousands of files to new role at PfizerAs two of the world’s largest pharmaceutical companies, Johnson & Johnson and Pfizer have long been rivals in various therapeutic areas. That made for an intriguing backdrop when a J&J employ2024/3/21
-
Novartis-backed MS network picks Seqster for data sharing pushThe Novartis-backed Multiple Sclerosis Implementation Network (MSIN) has joined forces with Seqster, harnessing the company’s data sharing operating system for a push to improve the management of the2024/3/18
-
Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertensionAfter Johnson & Johnson last yearchanged its mindon its 2017purchase of aprocitentan, the medicine's original maker has ushered the drugacross the FDA finish line. The once-daily drug, branded as2024/3/18
-
Lonza strikes $1.2B deal to buy mammoth Roche plant amid CDMO industry upheavalIn a bid to corner contracts on next-generation medicines, production juggernaut Lonza is picking up one of the world’s biggest biologics manufacturing facilities from its Swiss compatriot Roche. Lon2024/3/11
-
BioNTech's shares tumble—again—amid continued COVID vaccine sales slideFour months ago, when BioNTechslashedits 2023 revenue projection from 5 billion euros ($5.4 billion) to 4 billion euros ($4.3 billion), it was a jolting indication of the plummeting demand for COVID-2024/3/11
-
After Opdivo flop in liver cancer, Bristol Myers finds Yervoy combo could save livesBristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after an immunotherapy setback five years ago. The dual immunotherapy combination of Opdivo and Yervoy showed it ca2024/3/7
-
WuXi AppTec still sees sales growing and expansions rolling in 2024 despite concerns over US biosecurity billIn moments of great uncertainty, sometimes the best approach is to just press on. That seems to be the strategy being embraced at CDMO WuXi AppTec, whichissueda surprisingly upbeat 2024 forecast Mond2024/3/7
-
Takeda's Iclusig wins first-line FDA nod to treat rare Philadelphia chromosome-positive ALLTwelve years after Takeda'sIclusig (ponatinib) earned a restricted FDA approval to treat certain patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), the U.S. regulat2024/3/4
-
Riding GLP-1 wave, Novo Nordisk lays out $560M to boost drug production in ChinaThis year marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the company's red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian natio2024/3/4
-
IFF, after brief leadership stint under Merck's Frank Clyburn, pawns off pharma solutions business for $2.85BAfter a two-year stint under Merck & Co. veteran Frank Clyburn, New York’s International Flavors & Fragrances (IFF) is stripping away a major component of its healthcare persona. IFF—which da2024/3/1